A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Key facts
- Who runs it
- Qilu Pharmaceutical Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 420 people, planned
- Started
- 22 Jan 2026
- Expected to end
- Oct 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Meropenem and Pralurbactam
- Ceftazidime-avibactam
- Record updated
- 17 February 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- 1. Male or female participants ≥18 and ≤80 years of age; have a diagnosis of HAP/VAP; have systemic signs and respiratory signs or symptoms of HAP/VAP; New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening; The estimated survival time is at lest 28 days
Who cannot take part
- 1. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia; The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours; Acute Physiology and Chronic Health Evaluation (APACHE) II score >30; Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials; Those who have a history of drug abuse or drug abuse within 6 months before screening; Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.
The 2 groups in the trial
- Meropenem and PralurbactamTreatment being tested
- Ceftazidime-avibactamExisting treatment, for comparison
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam for Injection Compared to Ceftazidime and Avibactam Sodium for Injection in Subjects With Hospital-acquired and Ventilator-associated Bacterial Pneumonia
- Criteria questions
- Built from NCT07327619, who can take part
- Record updated
- 17 February 2026